Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes

• Published in: Terapevtic̆eskii arhiv Vol. 85; no. 7; pp. 65 - 71
• Main Authors: Dvirnyk, V N, Kokhno, A V, Glasko, E N, Gemdzhian, É G, Diagileva, O A, Platonova, T L, Parovichnikova, E N
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) "Consilium Medicum" Publishing house 01.01.2013
• Subjects: Adult; Aged; Antimetabolites, Antineoplastic - administration & dosage; Antimetabolites, Antineoplastic - adverse effects; Antimetabolites, Antineoplastic - therapeutic use; Azacitidine - administration & dosage; Azacitidine - adverse effects; Azacitidine - analogs & derivatives; Azacitidine - therapeutic use; cytology; decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; histology; Humans; Infusions, Intravenous; Male; Middle Aged; myelodysplastic syndrome; Myelodysplastic Syndromes - drug therapy; Myelodysplastic Syndromes - pathology; Myelopoiesis - drug effects; Prospective Studies; prospective trial; statistical frequency analysis; Treatment Outcome; Young Adult

To estimate a change in myelodysplasia in decitabine-treated patients with myelodysplastic syndromes (MDS). Thirteen MDS patients from a high-risk group were examined; 75 bone marrow puncture specimens and 67 bone marrow trepanobiopsy specimens from these patients were analyzed before and after deci...